The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 23 rounds in the feed, most often at Series B and in Biotech.
qimingvc.comRounds from 2018-03-28 to 2026-11-03
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Lingchuan Technology Lingchuan Technology offers intelligent video processing hardware and solutions, aimed at various industries requiring AI capabilities. | Series B Verified against 4 of 7 sources | $149.9M | 2026-11-03 | [ LEAD ] |
Yingjiexin Medical Develops and manufactures precision devices for administering pharmaceutical treatments | Series B |
| $30.1M |
| 2026-11-01 |
| [ PART ] |
Allygen Biologics Innovative biotechnology, targeted conjugate drugs | Series A Verified against 3 sources | $44.8M | 2026-10-13 | [ PART ] |
AlphaPai An AI investment research assistant developed by the financial AI company Rabyte Technology for professional investors | Series B Verified against 4 of 5 sources | $50M | 2026-09-15 | [ PART ] |
AusperBio Therapeutics, Inc. A startup developing therapeutics for chronic hepatitis B and other diseases | Series C Verified against 4 of 8 sources | $120M | 2026-08-27 | [ PART ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Crossover financing Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2026-05-04 | [ PART ] |
Pulnovo Medical Pulnovomed develops and conducts clinical trials for innovative treatments in pulmonary hypertension and heart failure, specifically focusing on pulmonary artery denervation technology. | Funding round Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-04-19 | [ PART ] |
Oricell Oricell develops cell therapies specifically aimed at treating cancer patients, particularly through advanced CAR-T technology. | Growth Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2026-04-09 | [ LEAD ] |
Shengshu Technology Shengshu sells advanced AI models for video generation and real-time interactive applications, targeting industries like entertainment, advertising, and education. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $86.5M | 2026-02-05 | [ PART ] |
Oricell Oricell develops cell therapies specifically aimed at treating cancer patients, particularly through advanced CAR-T technology. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $70M | 2026-01-12 | [ LEAD ] |
Green Energy Origin (GEO) Geosi sells advanced battery materials and specialty chemicals for electric vehicles and other industries transitioning to green energy. | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2025-12-10 | [ PART ] |
AusperBio Therapeutics, Inc. A startup developing therapeutics for chronic hepatitis B and other diseases | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $63M | 2025-09-22 | [ LEAD ] |
AusperBio Therapeutics, Inc. A startup developing therapeutics for chronic hepatitis B and other diseases | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $50M | 2025-05-28 | [ PART ] |
Pulnovo Medical Pulnovomed develops and conducts clinical trials for innovative treatments in pulmonary hypertension and heart failure, specifically focusing on pulmonary artery denervation technology. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-03-02 | [ LEAD ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-01-10 | [ PART ] |
AusperBio Therapeutics, Inc. A startup developing therapeutics for chronic hepatitis B and other diseases | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $73M | 2024-12-26 | [ PART ] |
AusperBio Therapeutics, Inc. A startup developing therapeutics for chronic hepatitis B and other diseases | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $37M | 2024-07-14 | [ PART ] |
Oricell Oricell develops cell therapies specifically aimed at treating cancer patients, particularly through advanced CAR-T technology. | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $45M | 2023-02-28 | [ PART ] |
DeepWay DeepWay builds autonomous freight robots and electric trucks for logistics. | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $67.2M | 2022-08-23 | [ LEAD ] |
Insilico Medicine AI-powered drug discovery and development tools to pharmaceutical companies and researchers. | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60M | 2022-06-06 | [ PART ] |
Insilico Medicine AI-powered drug discovery and development tools to pharmaceutical companies and researchers. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $255M | 2021-06-22 | [ PART ] |
Insilico Medicine AI-powered drug discovery and development tools to pharmaceutical companies and researchers. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $37M | 2019-09-10 | [ LEAD ] |
LetsGetChecked LetsGetChecked sells at-home health tests, telehealth services, and pharmacy solutions to individuals and businesses. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $12M | 2018-03-28 | [ LEAD ] |